Say Goodbye to Unwanted Facial Hair with Vaniqa – An Aussie Guide

Say Goodbye to Facial Hair with Vaniqa


Hirsutism or excessive male-pattern hair in women is caused by increased sensitivity of hair follicles to androgen hormones. It impacts 5-10% of Australian women. Most hirsutism cases result in vellus or coarse hairs on the upper lips, outer cheeks, jawline, and chin with exacerbated acne because of the sensitivity of sebaceous glands to facial hairs. 

Waxing and electrolysis, though feasible options are painful and expensive because topical treatment options like Vaniqa Cream are sought after because of their effectiveness and ease of application 

A word on Vaniqa 

Vaniqa or Eflornithine 13.9% is a topical prescription treatment option that slows down hair growth and softens coarse hair in 60% of women.


Image Credit – Rx only VANIQA® (eflornithine hydrochloride) cream, 13.9% For topical dermatological use only. Not for ophthalmic, oral, or intravaginal use.

It is important to understand the mechanism of hirsutism to have a better idea of the working of Vaniqa 13.6% 

Hirsutism is majorly the result of an excess of testosterone hormones that are converted by the 5-alpha reductase enzymes into Dihydrotestosterone. The DHT, in turn, binds with the hair follicles and, along with the supporting cushioning tissues, helps the hair follicles to forge deeper and stimulate mitosis in the early anagen phase of the follicle, the result being thick hair growing in copious amounts in the facial region and occasionally abdominal regions.

Screenshot 2024 07 08 202239

Image Credit –

How does Vaniqa work for hirsutism?

Vaniqa works on inhibiting Ornithine Decarboxylase, the enzyme responsible for catalyzing follicular polyamine synthesis, a crucial step for hair growth. 

Animal studies have shown Ornithine Decarboxylase and S-Adenosylmethionine decarboxylase are involved in the synthesis of polyamines and impact the length, diameter, and composition of hair fibers. 

Eflornithine works as a selective and irreversible inhibitor of ornithine decarboxylase and decreases putrescine and spermidine concentrations, the polyamines responsible for cellular proliferation to reduce facial hair growth to a moderate extent. 

We must understand that hair is one of the most proliferative organs of the human body and polyamines are crucial in the cellular processes for hair growth. By restricting polyamine synthesis, Vaniqa ( Eflornithine ) inhibits Ornithine Decarboxylase with a subsequent decrease in the structure and pattern of facial hair growth.

ijdvl 2007 73 5 365 35752 2

Image Credit –

Clinical studies conducted in Pennsylvania, USA have shown Eflornithine cream to be superior to placebo in reducing facial hair growth after 2 to 8 weeks of treatment. Percutaneous absorption of Eflornithine was less than 1%.

The medication was well tolerated with mild burning and tingling sensation being the most prominent. Hair Growth returned to a pretreatment state within eight weeks of discontinuing topical treatment. 

Overall through self-assessment questionnaires, researchers were able to conclude that Eflornithine use improved well-being and reduced the overall discomfort level because of unwanted facial hair by 33%.

It can be successfully combined with photoepilation. 

To evaluate the efficacy of combining Vaniqa with laser hair removal, 18 women were enrolled in a study. Each participant received five to six rounds of photoepilation ( laser and IPL ) on the face and neck prior to the study. Two days after the final laser round, Vaniqa was initiated into the treatment plan. Each participant was instructed to apply a thin layer of Vaniqa on half of their face, either right or left, twice daily for the next six months.

The results showed that the use of Vaniqa after laser reduced facial hair growth by 14% after one month and 17% after six months of application of the cream.

Other studies conducted on 19 women who applied Eflornithine after undergoing six rounds of laser treatments showed a 7.9% reduction in hair count within four weeks of treatment.

Care should be taken when using it in pregnant women. 

Based on numerous studies, it can be safely concluded that Vaniqa can be safely incorporated into the Aussie guide as a safe method of saying goodbye to unwanted hair. It has even been proved that out of every four hirsute women treated with a combination of Vaniqa and laser treatment, one will observe significant facial hair reduction. That said, Vaniqa is a prescription medication and should be used as per the advice of a physician. Care should be taken with its use in pregnant and lactating women, as animal studies have shown a marked decrease in fetal weight even at lower doses of the medication. 

In case the adverse reactions like burning or flushing persist or wosen, it would be best to continue its use and get urgent medical consultation.

Cause of Androgenic Alopecia: Crux of the Matter – PMC.

Ornithine Decarboxylase – an overview | ScienceDirect Topics.

Releated Articles